Absolutely. HABS‑HD is the most robust brain aging study among diverse communities in history. We have over 1,500 Hispanic, 1,500 Black, and 1,500 non-Hispanic whites, 30 and above enrolled, over 20,000 brain scans with over 10,000 PET scans. The blood biomarkers that are now hitting the market, we have on everyone. HABS‑HD was designed with the specific intent of understanding brain aging, Alzheimer’s disease biomarkers among representative communities within the context of sociocultural, environmental, and other factors...
Absolutely. HABS‑HD is the most robust brain aging study among diverse communities in history. We have over 1,500 Hispanic, 1,500 Black, and 1,500 non-Hispanic whites, 30 and above enrolled, over 20,000 brain scans with over 10,000 PET scans. The blood biomarkers that are now hitting the market, we have on everyone. HABS‑HD was designed with the specific intent of understanding brain aging, Alzheimer’s disease biomarkers among representative communities within the context of sociocultural, environmental, and other factors. So we go to the community. We don’t wait for the community to come to us. In doing so, what we have now shown is that the presence, progression, and even clinical impact of these Alzheimer’s biomarkers varies between groups. So where you come from matters. And medical comorbidities matter. Our science has said we really need to spend more time understanding our frameworks so that we can build precision medicine. The ultimate goal of HABS‑HD is precision medicine for all. Going back to what I said earlier, if I flip it to a positive statement, it is with representation of everyone, we will build precision medicine for anyone. So that’s the goal of HABS‑HD. And that’s what our science is really advancing at this point, making the field take a step back and say, okay, we need to pay more attention to these factors and now maybe think more broadly about the disease. For example, at CTAD, there was a meeting on cardiovascular factors and how do they play a role. So the field is really starting to think about multimodal therapies. And I think this is going to be relevant for all brain aging things. This isn’t just an Alzheimer’s concern. This is absolutely for multiple sclerosis, Parkinson’s disease, ALS, and just in general brain aging. So it’s exciting to see the work coming out in the field taking notice. And I think we’re definitely on, pardon me, we’re definitely on the road for a World of Optimal Brain Health for All, which is exciting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
